P0071 Diagnosis and treatment of coagulopathy following percutaneous cryoablation of liver tumours: Experience in 372 patients

jianping shi,lina niu,zhanpeng huang,feng mu,junjie chen,jianjun li,kun xu

DOI: https://doi.org/10.1016/j.ejca.2014.03.115

IF: 10.002

2014-01-01

European Journal of Cancer

Abstract:Background Coagulopathy after liver cryoablation was first reported many years ago; the cause is local platelet trapping and destruction within the margin of the cryolesion. However, the prognosis and therapeutic effects of coagulopathy remain unclear. Methods This study retrospectively reviewed clinical data from 372 patients (525 sessions) who underwent liver cryoablation in our hospital during the past 4.5 years. Small tumours (major diameter <6 cm) were treated with a single complete ablation; massive tumours (major diameter 6–10 cm or >10 cm) were divided into two or three parts that were dealt with in turn. Findings Platelet counts decreased to an average of 46.12 (± 68.13) ×109/L after each session of cryoablation. The decline was most evident in patients with high pretreatment platelet counts, while those with low pretreatment counts had the highest risk of coagulopathy. Change in platelet count was not correlated with the diameter of the tumour. Interpretation Slight coagulopathy (platelet count 70–100 × 109/L) can resolve without treatment within 1 week and administration of recombinant human interleukin-11 can assist recovery from severe coagulopathy (platelet count <70 × 109/L). Coagulopathy after liver cryoablation was first reported many years ago; the cause is local platelet trapping and destruction within the margin of the cryolesion. However, the prognosis and therapeutic effects of coagulopathy remain unclear. This study retrospectively reviewed clinical data from 372 patients (525 sessions) who underwent liver cryoablation in our hospital during the past 4.5 years. Small tumours (major diameter <6 cm) were treated with a single complete ablation; massive tumours (major diameter 6–10 cm or >10 cm) were divided into two or three parts that were dealt with in turn. Platelet counts decreased to an average of 46.12 (± 68.13) ×109/L after each session of cryoablation. The decline was most evident in patients with high pretreatment platelet counts, while those with low pretreatment counts had the highest risk of coagulopathy. Change in platelet count was not correlated with the diameter of the tumour. Slight coagulopathy (platelet count 70–100 × 109/L) can resolve without treatment within 1 week and administration of recombinant human interleukin-11 can assist recovery from severe coagulopathy (platelet count <70 × 109/L).